Immunotherapy for Prostate Cancer
- 19 June 2024
- book chapter
- Published by Nobel Tip Kitabevleri
- p. 131-139
Abstract
In this section, we reviewed immunotherapy for metastatic castration-resistant PCa (mCRPC), which is a promising area of research. Sipuleucel-T, a vaccine, showed some survival benefit but limited PSA decline. Other vaccines and immune checkpoint inhibitors are being tested with mixed results. CAR-T cell therapy, where T cells are engineered to target cancer cells, is also under investigation. More studies are needed to determine the best immunotherapies for PCa.Keywords
This publication has 10 references indexed in Scilit:
- Metastatic Castration-Resistant Prostate Cancer: Insights on Current Therapy and Promising Experimental DrugsResearch and Reports in Urology, 2023
- Vaccines as treatments for prostate cancerNature Reviews Urology, 2023
- Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trialNature Medicine, 2022
- KEYNOTE-641: A Phase III Study of Pembrolizumab Plus Enzalutamide for Metastatic Castration-Resistant Prostate CancerFuture Oncology, 2021
- Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate CancerDrugs, 2020
- Is There a Role for Immunotherapy in Prostate Cancer?Cells, 2020
- Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 StudyJournal of Clinical Oncology, 2020
- Immunotherapy for Prostate Cancer: Where We Are HeadedInternational Journal of Molecular Sciences, 2017
- Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trialThe Lancet Oncology, 2012
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010